China is in talks with Pfizer Inc. to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm’s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.
https://www.pharmalive.com/wp-content/uploads/2022/05/Pfizer-keeps-COVID-sales-forecast-unchanged-as-pandemic-curbs-ease-Reuters-5-3-22.webp503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-01-06 11:37:072023-01-06 12:16:45Exclusive: China in talks with Pfizer for generic COVID drug – sources